Synchrony Financial combines a 25.2% ROTCE, improving credit, durable merchant contracts, and aggressive buybacks with a 7.1x forward P/E, creating an attractive quality-lender value opportunity.
Overview
Synchrony Financial is a specialized U.S. consumer lender that embeds private-label, co-branded, general-purpose, promotional, and POS installment financing into retail and healthcare ecosystems. It earns interest and fee income on loan receivables while using Synchrony Bank deposits to optimize funding costs. Its competitive position is supported by approximately 40% of private-label card receivables, integrations across more than 500,000 merchant locations, PRISM underwriting using over 9,000 data points, and CareCredit’s 16 million cardholders and 200,000 providers. Q2 2026 showed record purchase volume of $49.8 billion, loan receivables of $102.2 billion, NIM of 15.08%, NCOs of 5.43%, and EPS of $2.59, although net income fell 8% to $885 million and the efficiency ratio rose to 35.8%. **The valuation is compelling at approximately 7.1x forward earnings**, supported by 25.2% ROTCE, 2.9% ROA, a 34.7% TTM net margin, a $0.34 dividend, and a $6.5 billion buyback authorization. Management raised 2026 EPS guidance to $9.25-$9.50. Near-term catalysts include Walmart OnePay scaling, improving credit, lower funding costs, buybacks, and the vacated CFPB late-fee cap.